Mesh.i
Checkpoint
PubMed
Racine
Checkpoint
PubMed
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Checkpoint (PubMed)

Index « Mesh.i » - entrée « Molecular Targeted Therapy »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Molecular Structure < Molecular Targeted Therapy < Monitoring, Immunologic  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 59.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000134 (2020) Peter Uciechowski [Allemagne] ; Wolfram C M. Dempke [Allemagne]Interleukin-6: A Masterplayer in the Cytokine Network.
000413 (2019) Masayoshi Harigai [Japon] ; Michi Tsutsumino [Japon] ; Hideto Takada [Japon] ; Kenji Nagasaka [Japon]Molecular targeted therapies for microscopic polyangiitis and granulomatosis with polyangiitis.
000453 (2019) N. Kamiya [Japon] ; G. Kuroyanagi [États-Unis] ; O. Aruwajoye [États-Unis] ; H K W. Kim [États-Unis]IL6 receptor blockade preserves articular cartilage and increases bone volume following ischemic osteonecrosis in immature mice.
000598 (2018) Hirofumi Jono[Establishing Individualized Medicine for Intractable Cancer Based on Clinical Molecular Pathogenesis].
000660 (2018) Christopher P. Denton [Royaume-Uni] ; Voon H. Ong [Royaume-Uni] ; Shiwen Xu [Royaume-Uni] ; Haiyin Chen-Harris [États-Unis] ; Zora Modrusan [États-Unis] ; Robert Lafyatis [États-Unis] ; Dinesh Khanna [États-Unis] ; Angelika Jahreis [États-Unis] ; Jeffrey Siegel [États-Unis] ; Thierry Sornasse [États-Unis]Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
000668 (2018) Masashi Narazaki [Japon] ; Tadamitsu Kishimoto [Japon]The Two-Faced Cytokine IL-6 in Host Defense and Diseases.
000693 (2018) Francesca Bartoli [Italie] ; Sangmee Bae [États-Unis] ; Laura Cometi [Italie] ; Marco Matucci Cerinic [Italie] ; Daniel E. Furst [États-Unis]Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018.
000725 (2018) M. Guevara [États-Unis] ; C S Kollipara [États-Unis]Recent Advances in Giant Cell Arteritis.
000784 (2018) Hiroki Wakabayashi [Japon] ; Takahiko Hamaguchi [Japon] ; Nobuto Nagao [Japon] ; Sho Kato [Japon] ; Takahiro Iino [Japon] ; Tomoki Nakamura [Japon] ; Akihiro Sudo [Japon]Interleukin-6 receptor inhibitor suppresses bone metastases in a breast cancer cell line.
000841 (2018) Paul Emery [Royaume-Uni] ; Janet E. Pope [Canada] ; Klaus Kruger [Allemagne] ; Ralph Lippe [Allemagne] ; Ryan Demasi [États-Unis] ; Sadiq Lula [Royaume-Uni] ; Blerina Kola [Royaume-Uni]Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review.
000857 (2018) K L Winthrop [États-Unis] ; X. Mariette [France] ; J T Silva [Espagne] ; E. Benamu [États-Unis] ; L H Calabrese [États-Unis] ; A. Dumusc [Suisse] ; J S Smolen [Autriche] ; J M Aguado [Espagne] ; M. Fernández-Ruiz [Espagne]ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).
000953 (2017) M. Samson [France] ; B. Bonnotte [France][From pathogenesis of giant cell arteritis to new therapeutic targets].
000A44 (2017) Hasini Jayatilaka [États-Unis] ; Pranay Tyle [États-Unis] ; Jonathan J. Chen [États-Unis] ; Minsuk Kwak [États-Unis] ; Julia Ju [États-Unis] ; Hyun Ji Kim [États-Unis] ; Jerry S H. Lee [États-Unis] ; Pei-Hsun Wu [États-Unis] ; Daniele M. Gilkes [États-Unis] ; Rong Fan [États-Unis] ; Denis Wirtz [États-Unis]Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration.
000A80 (2017) Laurie S. Davis ; Andreas M. ReimoldResearch and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.
000B25 (2017) Stanley C. Jordan [États-Unis] ; Jua Choi ; Irene Kim ; Gordon Wu ; Mieko Toyoda ; Bonga Shin ; Ashley VoInterleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade.
000C32 (2017) Chen Tian [République populaire de Chine] ; Hongliang Yang [République populaire de Chine] ; Lei Zhu [République populaire de Chine] ; Qing Zhang [République populaire de Chine] ; Zeng Cao [République populaire de Chine] ; Yizhuo Zhang [République populaire de Chine]Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement.
000C66 (2016) Yuko Kaneko ; Tsutomu Takeuchi[IL-6 blockade].
000C71 (2016) Ayako Nakajima[Cardiovascular diseases in rheumatoid arthritis].
000D20 (2016) Xiao Liu [Royaume-Uni] ; Gareth W. Jones ; Ernest H. Choy ; Simon A. JonesThe biology behind interleukin-6 targeted interventions.
000D77 (2016) Chris Hughes [Royaume-Uni] ; Ahuva Nissim [Royaume-Uni]Progress and clinical potential of antibody-targeted therapy for arthritic damage.
000D95 (2016) Joachim Sieper [Allemagne]New treatment targets for axial spondyloarthritis.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/Mesh.i -k "Molecular Targeted Therapy" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/Mesh.i  \
                -Sk "Molecular Targeted Therapy" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Molecular Targeted Therapy
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021